{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"description":"An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as AEs with an onset date on or after the first dose of Study drug, and within 30 days of the last dose of study drug or prior to the start of a new anticancer treatment, whichever occurred first. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","groups":[{"description":"Participants received single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg AIBW administered IV on Day 1 of every 3-week cycle (Q3W).","id":"OG000","title":"Mirvetuximab Soravtansine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety population was defined as participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to approximately 27 months","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}